SANDUPHQPharmaceuticals
Sandu Pharmaceuticals, Inc — Profit & Loss Statement
₹30.52
-6.58%
Sandu Pharmaceuticals, Inc Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Tax Effect Of Unusual Items | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Tax Rate For Calcs | 0.28 | 0.30 | 0.31 | 0.31 | — |
| Normalized EBITDA | 2.93 Cr | 2.72 Cr | 2.81 Cr | 2.96 Cr | — |
| Net Income From Continuing Operation Net Minority Interest | 1.55 Cr | 1.46 Cr | 1.52 Cr | 1.59 Cr | — |
| Reconciled Depreciation | 0.67 Cr | 0.58 Cr | 0.52 Cr | 0.53 Cr | — |
| Reconciled Cost Of Revenue | 32.10 Cr | 32.57 Cr | 32.26 Cr | 35.74 Cr | — |
| EBITDA | 2.93 Cr | 2.72 Cr | 2.81 Cr | 2.96 Cr | — |
| EBIT | 2.26 Cr | 2.14 Cr | 2.29 Cr | 2.43 Cr | — |
| Net Interest Income | -0.10 Cr | -0.06 Cr | 0.08 Cr | -0.11 Cr | — |
| Interest Expense | 0.10 Cr | 0.06 Cr | 0.07 Cr | 0.11 Cr | — |
| Normalized Income | 1.55 Cr | 1.46 Cr | 1.52 Cr | 1.59 Cr | — |
| Net Income From Continuing And Discontinued Operation | 1.55 Cr | 1.46 Cr | 1.52 Cr | 1.59 Cr | — |
| Total Expenses | 65.10 Cr | 65.57 Cr | 63.38 Cr | 63.16 Cr | — |
| Diluted NI Availto Com Stockholders | 1.55 Cr | 1.46 Cr | 1.52 Cr | 1.59 Cr | — |
| Net Income Common Stockholders | 1.55 Cr | 1.46 Cr | 1.52 Cr | 1.59 Cr | — |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income | 1.55 Cr | 1.46 Cr | 1.52 Cr | 1.59 Cr | — |
| Net Income Including Noncontrolling Interests | 1.55 Cr | 1.46 Cr | 1.52 Cr | 1.59 Cr | — |
| Net Income Continuous Operations | 1.55 Cr | 1.46 Cr | 1.52 Cr | 1.59 Cr | — |
| Tax Provision | 0.61 Cr | 0.61 Cr | 0.70 Cr | 0.73 Cr | — |
| Pretax Income | 2.16 Cr | 2.07 Cr | 2.22 Cr | 2.32 Cr | — |
| Other Non Operating Income Expenses | 0.17 Cr | 0.42 Cr | 0.33 Cr | 0.08 Cr | — |
| Net Non Operating Interest Income Expense | -0.10 Cr | -0.06 Cr | 0.08 Cr | -0.11 Cr | — |
| Interest Expense Non Operating | 0.10 Cr | 0.06 Cr | 0.07 Cr | 0.11 Cr | — |
| Operating Income | 2.09 Cr | 1.71 Cr | 1.97 Cr | 2.34 Cr | — |
| Operating Expense | 33.00 Cr | 33.00 Cr | 31.12 Cr | 27.41 Cr | — |
| Other Operating Expenses | 21.41 Cr | 22.34 Cr | 8.54 Cr | 17.97 Cr | — |
| Depreciation And Amortization In Income Statement | 0.67 Cr | 0.58 Cr | 0.52 Cr | 0.53 Cr | — |
| Depreciation Income Statement | 0.67 Cr | 0.58 Cr | 0.52 Cr | 0.53 Cr | — |
| Gross Profit | 35.09 Cr | 34.71 Cr | 33.09 Cr | 29.76 Cr | — |
| Cost Of Revenue | 32.10 Cr | 32.57 Cr | 32.26 Cr | 35.74 Cr | — |
| Total Revenue | 67.19 Cr | 67.28 Cr | 65.35 Cr | 65.50 Cr | — |
| Operating Revenue | 67.19 Cr | 67.28 Cr | 65.35 Cr | 65.50 Cr | — |
| Total Unusual Items | — | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Unusual Items Excluding Goodwill | — | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Income | — | 0.16 Cr | 0.16 Cr | 0.08 Cr | 0.19 Cr |
| Rent Expense Supplemental | — | 0.24 Cr | 0.22 Cr | 0.21 Cr | 0.27 Cr |
| Diluted Average Shares | — | 0.97 Cr | 0.94 Cr | 0.85 Cr | 0.71 Cr |
| Basic Average Shares | — | 0.97 Cr | 0.88 Cr | 0.80 Cr | 0.71 Cr |
| Diluted EPS | — | 1.51 | 1.62 | 1.87 | 1.54 |
| Basic EPS | — | 1.51 | 1.62 | 1.99 | 1.54 |
| Special Income Charges | — | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Other Finance Cost | — | 87000.00 | 75000.00 | 0.04 Cr | 0.05 Cr |
| Interest Income Non Operating | — | 0.16 Cr | 0.16 Cr | 0.08 Cr | 0.19 Cr |
| Research And Development | — | 0.11 Cr | 0.12 Cr | 0.16 Cr | 0.14 Cr |
| Selling General And Administration | — | 12.69 Cr | 10.62 Cr | 9.51 Cr | 7.65 Cr |
| Selling And Marketing Expense | — | 11.71 Cr | 9.71 Cr | 8.51 Cr | 6.90 Cr |
| General And Administrative Expense | — | 0.97 Cr | 0.91 Cr | 1.00 Cr | 0.75 Cr |
| Rent And Landing Fees | — | 0.24 Cr | 0.22 Cr | 0.21 Cr | 0.27 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Sandu Pharmaceuticals, Inc
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.